27-08-2020
Sundry Photography / Shutterstock.com
Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel (etanercept).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, Sandoz, Immunex, biologics, Federal Circuit, Enbrel, rheumatoid arthritis, patent exclusivity, gamesmanship, Roche
SCOTUS declines patents review on Enbrel drug
18-05-2021
English court resumes Amgen cholesterol patent suit
23-10-2020
Fed Circuit affirms cancellation of Anacor antifungal patents
01-09-2020
Sandoz gains backing for Enbrel patent term review
20-08-2020
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
02-07-2020
